Ischemic heart disease after renal transplantation

Bertram L. Kasiske, Jordan J. Cohen, John T. Harrington, Nicolaos E. Madias, Hamid Rabb, Mark Rosenberg, Charles A. Herzog, Michael Aaronson, Horacio Esteban Adrogué, Shakeel Anjum, Robert Berkseth

Research output: Contribution to journalArticle

Abstract

Dramatic improvements in renal allograft survival over the last 10 years have shifted the focus of posttransplant management from short-term considerations to reduction of deaths due to IHD (and other causes) over the long term. A growing body of evidence suggests that the high incidence of IHD after renal transplantation is in large part due to the high prevalence of traditional risk factors such as hypertension and hyperlipidemia. It is neither feasible nor necessary to demonstrate that treating risk factors like elevated blood pressure and LDL cholesterol is justified in reducing morbidity and mortality from IHD. Recent data suggest that the incidence of IHD is declining in some centers [16], likely because of the use of new medications that effectively reduce factors for IHD. Further emphasis on managing these risk factors, along with additional studies to identify new prevention strategies, are needed if progress in reducing this major cause of death in transplant patients is to continue.

Original languageEnglish (US)
Pages (from-to)356-369
Number of pages14
JournalKidney International
Volume61
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Kidney Transplantation
Myocardial Ischemia
Incidence
Hyperlipidemias
LDL Cholesterol
Allografts
Cause of Death
Blood Pressure
Hypertension
Morbidity
Transplants
Kidney
Mortality

Keywords

  • HDL cholesterol
  • LDL cholesterol
  • Myocardial infarction

ASJC Scopus subject areas

  • Nephrology

Cite this

Kasiske, B. L., Cohen, J. J., Harrington, J. T., Madias, N. E., Rabb, H., Rosenberg, M., ... Berkseth, R. (2002). Ischemic heart disease after renal transplantation. Kidney International, 61(1), 356-369. https://doi.org/10.1046/j.1523-1755.2002.00121.x

Ischemic heart disease after renal transplantation. / Kasiske, Bertram L.; Cohen, Jordan J.; Harrington, John T.; Madias, Nicolaos E.; Rabb, Hamid; Rosenberg, Mark; Herzog, Charles A.; Aaronson, Michael; Adrogué, Horacio Esteban; Anjum, Shakeel; Berkseth, Robert.

In: Kidney International, Vol. 61, No. 1, 2002, p. 356-369.

Research output: Contribution to journalArticle

Kasiske, BL, Cohen, JJ, Harrington, JT, Madias, NE, Rabb, H, Rosenberg, M, Herzog, CA, Aaronson, M, Adrogué, HE, Anjum, S & Berkseth, R 2002, 'Ischemic heart disease after renal transplantation', Kidney International, vol. 61, no. 1, pp. 356-369. https://doi.org/10.1046/j.1523-1755.2002.00121.x
Kasiske BL, Cohen JJ, Harrington JT, Madias NE, Rabb H, Rosenberg M et al. Ischemic heart disease after renal transplantation. Kidney International. 2002;61(1):356-369. https://doi.org/10.1046/j.1523-1755.2002.00121.x
Kasiske, Bertram L. ; Cohen, Jordan J. ; Harrington, John T. ; Madias, Nicolaos E. ; Rabb, Hamid ; Rosenberg, Mark ; Herzog, Charles A. ; Aaronson, Michael ; Adrogué, Horacio Esteban ; Anjum, Shakeel ; Berkseth, Robert. / Ischemic heart disease after renal transplantation. In: Kidney International. 2002 ; Vol. 61, No. 1. pp. 356-369.
@article{958bc4a3425b43fa95fead5af794114d,
title = "Ischemic heart disease after renal transplantation",
abstract = "Dramatic improvements in renal allograft survival over the last 10 years have shifted the focus of posttransplant management from short-term considerations to reduction of deaths due to IHD (and other causes) over the long term. A growing body of evidence suggests that the high incidence of IHD after renal transplantation is in large part due to the high prevalence of traditional risk factors such as hypertension and hyperlipidemia. It is neither feasible nor necessary to demonstrate that treating risk factors like elevated blood pressure and LDL cholesterol is justified in reducing morbidity and mortality from IHD. Recent data suggest that the incidence of IHD is declining in some centers [16], likely because of the use of new medications that effectively reduce factors for IHD. Further emphasis on managing these risk factors, along with additional studies to identify new prevention strategies, are needed if progress in reducing this major cause of death in transplant patients is to continue.",
keywords = "HDL cholesterol, LDL cholesterol, Myocardial infarction",
author = "Kasiske, {Bertram L.} and Cohen, {Jordan J.} and Harrington, {John T.} and Madias, {Nicolaos E.} and Hamid Rabb and Mark Rosenberg and Herzog, {Charles A.} and Michael Aaronson and Adrogu{\'e}, {Horacio Esteban} and Shakeel Anjum and Robert Berkseth",
year = "2002",
doi = "10.1046/j.1523-1755.2002.00121.x",
language = "English (US)",
volume = "61",
pages = "356--369",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Ischemic heart disease after renal transplantation

AU - Kasiske, Bertram L.

AU - Cohen, Jordan J.

AU - Harrington, John T.

AU - Madias, Nicolaos E.

AU - Rabb, Hamid

AU - Rosenberg, Mark

AU - Herzog, Charles A.

AU - Aaronson, Michael

AU - Adrogué, Horacio Esteban

AU - Anjum, Shakeel

AU - Berkseth, Robert

PY - 2002

Y1 - 2002

N2 - Dramatic improvements in renal allograft survival over the last 10 years have shifted the focus of posttransplant management from short-term considerations to reduction of deaths due to IHD (and other causes) over the long term. A growing body of evidence suggests that the high incidence of IHD after renal transplantation is in large part due to the high prevalence of traditional risk factors such as hypertension and hyperlipidemia. It is neither feasible nor necessary to demonstrate that treating risk factors like elevated blood pressure and LDL cholesterol is justified in reducing morbidity and mortality from IHD. Recent data suggest that the incidence of IHD is declining in some centers [16], likely because of the use of new medications that effectively reduce factors for IHD. Further emphasis on managing these risk factors, along with additional studies to identify new prevention strategies, are needed if progress in reducing this major cause of death in transplant patients is to continue.

AB - Dramatic improvements in renal allograft survival over the last 10 years have shifted the focus of posttransplant management from short-term considerations to reduction of deaths due to IHD (and other causes) over the long term. A growing body of evidence suggests that the high incidence of IHD after renal transplantation is in large part due to the high prevalence of traditional risk factors such as hypertension and hyperlipidemia. It is neither feasible nor necessary to demonstrate that treating risk factors like elevated blood pressure and LDL cholesterol is justified in reducing morbidity and mortality from IHD. Recent data suggest that the incidence of IHD is declining in some centers [16], likely because of the use of new medications that effectively reduce factors for IHD. Further emphasis on managing these risk factors, along with additional studies to identify new prevention strategies, are needed if progress in reducing this major cause of death in transplant patients is to continue.

KW - HDL cholesterol

KW - LDL cholesterol

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=0036149250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036149250&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.2002.00121.x

DO - 10.1046/j.1523-1755.2002.00121.x

M3 - Article

C2 - 11786124

AN - SCOPUS:0036149250

VL - 61

SP - 356

EP - 369

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 1

ER -